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Abstract
Background: Microglia are active modulators of Alzheimer’s disease but their role in relation to amyloid plaques
and synaptic changes due to rising amyloid beta is unclear. We add novel findings concerning these relationships
and investigate which of our previously reported results from transgenic mice can be validated in knock-in mice, in
which overexpression and other artefacts of transgenic technology are avoided.
Methods: AppNL-F and AppNL-G-F knock-in mice expressing humanised amyloid beta with mutations in App that
cause familial Alzheimer’s disease were compared to wild type mice throughout life. In vitro approaches were used
to understand microglial alterations at the genetic and protein levels and synaptic function and plasticity in CA1
hippocampal neurones, each in relationship to both age and stage of amyloid beta pathology. The contribution of
microglia to neuronal function was further investigated by ablating microglia with CSF1R inhibitor PLX5622.
Results: Both App knock-in lines showed increased glutamate release probability prior to detection of plaques.
Consistent with results in transgenic mice, this persisted throughout life in AppNL-F mice but was not evident in
AppNL-G-F with sparse plaques. Unlike transgenic mice, loss of spontaneous excitatory activity only occurred at the
latest stages, while no change could be detected in spontaneous inhibitory synaptic transmission or magnitude of
long-term potentiation. Also, in contrast to transgenic mice, the microglial response in both App knock-in lines was
delayed until a moderate plaque load developed. Surviving PLX5266-depleted microglia tended to be CD68-
positive. Partial microglial ablation led to aged but not young wild type animals mimicking the increased glutamate
release probability in App knock-ins and exacerbated the App knock-in phenotype. Complete ablation was less
effective in altering synaptic function, while neither treatment altered plaque load.
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Conclusions: Increased glutamate release probability is similar across knock-in and transgenic mouse models of
Alzheimer’s disease, likely reflecting acute physiological effects of soluble amyloid beta. Microglia respond later to
increased amyloid beta levels by proliferating and upregulating Cd68 and Trem2. Partial depletion of microglia
suggests that, in wild type mice, alteration of surviving phagocytic microglia, rather than microglial loss, drives age-
dependent effects on glutamate release that become exacerbated in Alzheimer’s disease.
Keywords: Synaptic transmission, Synaptic plasticity, Microglia, Alzheimer’s disease, Gene expression,
Neurodegeneration, TREM2, Ageing, Amyloid beta, Plaques
Background
All research models present limitations and this is par-
ticularly true for Alzheimer’s disease, where there is an
urgent need to understand disease progression. Until re-
cently, most mouse models relied on transgenesis to ex-
press genes that cause inherited forms of the disease
(reviewed in [1]). This has been a useful tool to initiate
rising amyloid beta (Aβ) levels, a proposed trigger for
sporadic Alzheimer’s disease; however, although these
mice develop substantial plaque loads, they fail to de-
velop tau tangles or extensive neurodegeneration. Fur-
thermore, the overexpression of APP, inappropriate
distribution and timing of expression due to ectopic pro-
moters and disruption of off-target genes by random
transgene insertion sites have raised questions over the
relevance of reported findings [2]. In particular, overex-
pression of APP results in not only raised Aβ but also
other APP metabolites, the levels of which may not be
increased to any substantial degree in Alzheimer’s dis-
ease [3]. Such metabolites have physiological effects (for
example [4] and reviewed in [5]) that may become evi-
dent in transgenic mice but be less relevant to Alzhei-
mer’s disease.
Transgenic mice show early alterations in synaptic
transmission and plasticity (for example [6, 7–10]), along-
side proliferation and activation of microglia around pla-
ques [10–13]. These microglial changes are of particular
interest, as many genes with variants associated with Alz-
heimer’s disease are expressed by microglia [14] and, fur-
thermore, are also altered in transgenic mice [15–17].
These studies have led to various hypotheses concerning
the physiological versus pathological roles of microglia in
disease progression (discussed in [18, 19, 20]).
Given the question of relevance to human disease of
phenotypes obtained in transgenic mice, we employed
App knock-in mouse models in which the Aβ sequence
within App has been humanised [21]. In particular we
use the AppNL-F line, harbouring Swedish and Iberian/
Beyreuther mutations, resulting in raised total Aβ [22]
and raised Αβ42:Aβ40 ratio [23], respectively. An in-
crease in Aβ levels and a raised Αβ42:Aβ40 ratio are also
features of sporadic AD, albeit not arising from muta-
tions in APP [24]. We also compare AppNL-F to
AppNL-G-F mice that additionally harbour the Arctic
mutation, which changes the Aβ sequence, rendering it
more susceptible to fibrillation [25]. It should be noted
that, similar to transgenic mice, both models display tau
hyperphosphorylation but fail to develop tangles or sub-
stantial neurodegeneration, even with humanised
Mapt (encoding the protein tau; [26]).
Here we report phenotypes consistent with and con-
trasting to our previously published results obtained in
transgenic mice [9, 10]; initial results published in [27].
Alterations in excitatory synaptic transmission and plas-
ticity were examined in App knock-in mouse hippocam-
pus at stages prior to plaque deposition through to old
age. Furthermore, we investigated the microglial contri-
bution to these using an inhibitor of the microglial sur-
vival factor CSF1R [28], resulting in little effect on
plaque development but a complex synaptic phenotype
in which partial depletion of microglia had more sub-
stantial effects than near-complete ablation.
Methods
See Additional file 1 for complete Methods.
Animals
Experiments were performed in accordance with the UK
Animal (Scientific Procedures) Act 1986 and following
local ethical review. Homozygous App knock-in mice
and wild type counterparts were group housed (2–5
mice) with ad libitum supply of food and water.
Animals were decapitated, the brain rapidly extracted
and bisected. One hemisphere was drop-fixed in 10%
formalin for histology; the other was processed for elec-
trophysiology or RNA extraction.
Genotyping
Genomic DNA was extracted and standard PCR reactions
performed to identify the presence of the knock-in genes.
Histology
Brain sections (30 μm) transverse to the long axis of the
hippocampus were prepared and processed as free-
floating sections and nuclei counterstained with 4′,6-dia-
midino-2-phenylindole (DAPI).
Plaques were labelled with luminescent conjugated oli-
gothiophenes (LCOs; [29]).
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Immunohistochemical experiments employed standard
techniques [10]. Sections were permeabilised, non-
specific binding blocked, then incubated with primary
antibodies (1:500 rabbit anti-IBA1; or 1:500 rat anti-
CD68) overnight at 4 °C, followed by Alexa-conjugated
secondary antibodies for 2 h at room temperature in the
dark.
Imaging and data analysis
Epifluorescent photomicrographs of whole hippocampal
regions within sections were obtained under a 20× ob-
jective by area-defined serial scanning with constant
light, gain and exposure settings. Three sections per ani-
mal were assessed.
To determine cell densities, three non-overlapping
areas of interest were defined and IBA1+ microglia
counted only if the associated DAPI+ nucleus was
evident.
To establish plaque size histograms, the hippocampal
area within each section was defined and a colour inten-
sity threshold set to differentiate LCOs signal from back-
ground and pixel coverage determined.
Acute brain slice preparation for electrophysiology
Following decapitation, the extracted brain hemisphere
was placed in ice-cold dissection artificial CSF (aCSF;
raised Mg++ and reduced Ca++ ion concentrations).
Brain slices (400 μm) transverse to the long axis of the
hippocampus were cut, then incrementally changed
through a series of heated (35 °C) aCSF solutions to a
physiological recording aCSF (containing 1 mM Mg2+
and 2mM Ca2+) bubbled with 95% O2/5% CO2.
Patch-clamp recordings
Slices were allowed to recover at room temperature be-
fore a single slice was transferred to a submerged cham-
ber and superfused with recording aCSF. Visualised CA1
pyramidal neurones were voltage-clamped in whole cell
mode using glass electrodes (tip resistance 4–6MΩ)
filled with CsCl-based internal solution. Standard patch-
clamp apparatus were used [9], with signal low-pass fil-
tered sequentially at 10 kHz then 3 kHz and digitised at
10 kHz.
Initially, spontaneous currents were recorded in the
absence of neurotransmitter receptor antagonists at a
membrane holding potential of -70 mV. Around 90–95%
of events under these conditions are inhibitory postsyn-
aptic currents; the remainder being excitatory. Subse-
quently, excitatory postsynaptic currents were isolated
by introducing gabazine. Spontaneous and miniature
(with the addition of tetrodotoxin) currents were then
recorded. Spontaneous and miniature currents were de-
tected using an automated algorithm and inspected by
eye for integrity.
Evoked currents were recorded in the presence of
gabazine. Stimuli were applied via a patch electrode
filled with aCSF and positioned in stratum radiatum of
CA1, ~ 150–300 μm from the recording electrode. To
establish failure rates, unitary responses were evoked by
minimal stimulation. For all other experiments, stimulus
intensity was set at near-minimal stimulation, such that
~ 50–80% of stimuli evoked a response.
Field potential recordings in brain slices
Field potentials were recorded using standard protocols
[10]. Slices were submerged in a heated (30 ± 1 °C)
chamber, superfused with aCSF and allowed to recover
for 1 h. Recording and stimulating electrodes (filled with
aCSF, resistance ~ 2MΩ) were both positioned in
stratum radiatum of CA1, ~ 150–300 μm apart, to ob-
tain dendritic excitatory postsynaptic field potentials
(fEPSPs) in the absence of GABAA receptor antagonists.
Field potentials were low-pass filtered serially at 10 kHz
and 3 kHz and digitised at 10 kHz. Stimulation intensity
was set to evoke fEPSPs subthreshold to a population
spike. Pairs of stimuli (50 ms inter-stimulus interval)
were applied at 0·1 Hz. Long-term potentiation (LTP)
conditioning consisted of three tetanus trains, each of
twenty stimuli at 100 Hz, 1·5 s inter-train interval, ap-
plied at test-pulse stimulus intensity. Responses in each
1-min period were averaged and the slope of the first
fEPSP and the paired-pulse ratio of each pair calculated
as percent of the respective average baseline.
Hippocampal homogenisation and RNA extraction
Whole hippocampus was extracted, snap-frozen, then
homogenised in RNA lysis reagent. Chloroform was
added to the lysate for phase separation. Following cen-
trifugation, total RNA was extracted and DNA digested.
Concentration and quality of RNA were assessed using a
spectrophotometer and the A260/A280 ratios calculated.
Total RNA solutions were stored at − 80 °C.
Reverse transcription
RNA samples were treated with RNaseOUT and amplifi-
cation grade DNaseI and placed in a thermocycler
followed by an enzymatic denaturation step. Reverse-
transcription was then performed using a High Capacity
cDNA Reverse Transcription kit. Following a thermo-
cycle step, cDNA was diluted and stored at − 20 °C.
Real time-quantitative PCR
cDNA was tested in triplicate using SsoAdvanced Uni-
versal SYBR Green Supermix, both forward and reverse
primers and cDNA diluted in nuclease-free water. Nega-
tive controls from the reverse-transcription protocol
were included to test for the presence of genomic DNA
or contamination. A blank control was included that
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replaced the cDNA solution with nuclease-free water. A
melt curve was produced using a standard thermocycling
protocol. All reactions were tested for the presence of a
single PCR product.
Microglial ablation
Microglia were removed from the brain by feeding mice
the CSF1R antagonist PLX5622. Cages of male mice
were randomly assigned to either control or test groups.
The standard grain-based diet mice are fed was changed
to a refined diet supplemented with either vehicle or
PLX5622.
Analyses
All analyses were performed by experimenters blinded
to genotype and experimental conditions. Where mul-
tiple samples/cells/slices/sections were obtained from a
single animal, a mean value was calculated for that ani-
mal, avoiding false replication from non-independent
samples. Age- and sex-matched wild types were inter-
leaved with AppNL-F and AppNL-G-F mice and thus act as
common controls for both genotypes.
Data availability
The data that support the findings of this study are




Plaque development in the current App knock-in mice
was quantified using a 0–5 rating scale of sections la-
belled with LCOs (Supplementary Fig. 1). In AppNL-F
mice (Fig. 1a, c and Supplementary Fig. 2 for 7 months),
the first sparse, small plaques were detected at 9-
months-old but were not detected in all sections. By 14-
months-old, plaques were reliably detected but were still
small and sparse. At 18- and 24-months-old, plaques of
a range of sizes were spread across the hippocampus.
While pathology scores increased with age, there was no
effect of sex at any given age (Kruskal-Wallis test com-
paring 8 groups p < 0·00001, followed by Dunn’s multiple
comparisons between all groups, p > 0·5 between sexes
at all ages).
In 2-months-old AppNL-G-F mice (Fig. 1b, c), only a
few small plaques were detected. In 4-month-old ani-
mals, the plaque load was already heavier than in the 24-
month-old AppNL-F mice. By 9-month-old, a substantial
plaque load was evident, with little further increase
through to the oldest ages. While there was an increase
in pathology score with age, there were no significant ef-
fect of sex at any given age (Kruskal-Wallis test compar-
ing 10 groups p < 0·0001, followed by Dunn’s multiple
comparisons between all groups (p > 0·5 between sexes
at all ages).
Spontaneous and miniature excitatory postsynaptic
currents
Synaptic transmission was examined in patch-clamp re-
cordings of CA1 pyramidal neurones in voltage-clamp
mode to record excitatory postsynaptic currents (EPSCs)
in slices prepared from male mice (Fig. 2A). Recordings
were made at different ages to facilitate comparisons of
effects at a given stage of plaque development in the two
genotypes or at the equivalent age.
The frequency of spontaneous EPSCs in slices were
compared using a generalised linear mixed model
(GLMM) designed to assess the effect of genotype within
a given age. The genotype within age term was signifi-
cant (p = 0·00069) and thus simple post hoc comparisons
with sequential Sidak corrections were made for geno-
type within each age; Fig. 2Bi). There were no significant
differences across the youngest ages. At 9-months-old,
the lower frequency in AppNL-G-F compared to wild type
reached p = 0·025. By 20-months-old, spontaneous
EPSCs occurred at lower frequencies than wild types in
both AppNL-F (p = 0·018) and AppNL-G-F (p = 0·00028)
mice. There were no significant effects for EPSC ampli-
tude or time constant (Fig. 2Bii-iii) at any age.
When miniature EPSCs were isolated, no significant
differences between genotypes or ages were identified in
terms of frequency, amplitude or decay (GLMM; Fig. 2
Ci-iii).
Paired-pulse ratios
Pairs of stimuli were applied to Schaffer collaterals to
evoke EPSCs (Fig. 3). Typical of CA3-CA1 synapses,
paired-pulse facilitation (i.e. the second EPSC amplitude
greater than the first, indicative of a low probability of
glutamate release; see reference [30] for review) was ob-
served in slices from wild type animals at all ages. As ex-
pected, facilitation decreased with longer inter-stimulus
intervals.
At 2-months-old, when only rare, small plaques were
detected, AppNL-G-F mice showed a reduced paired-pulse
facilitation compared to wild types (two-way ANOVA,
genotype × inter-stimulus interval interaction p = 0·0074;
Sidak multiple comparisons: 25 ms p = 0·017; 50 ms, p =
0·3), indicative of a higher probability of glutamate re-
lease in AppNL-G-F.
At 4-months-old, when moderate plaque deposition is
seen, AppNL-G-F mice no longer showed reduced paired-
pulse ratios compared to wild types. While a main effect
of inter-stimulus interval remained (p = 0·0011), there
was no effect of genotype (p = 0·3) nor an interaction
(p > 0·5).
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In AppNL-F mice, while there were no differences de-
tected at 4-months-old, paired-pulse ratio was decreased
at 7-months-old, before plaques were detected (main ef-
fects of genotype, p = 0·038 and inter-stimulus interval,
p = 0·002; no interaction, p = 0·14).
Interestingly, at 9-months-old, when dense plaques
were present in AppNL-G-F mice, the decreased paired-
pulse ratio was again evident. AppNL-F mice also main-
tained the decreased paired-pulse ratio at this age. When
the knock-in genotypes were compared to wild type
mice, two-way ANOVA showed a significant effect of
genotype (p = 0·0005) but no significant effect of inter-
stimulus interval or an interaction. Hence, AppNL-F and
AppNL-G-F mice had similarly lower paired-pulse ratios,
despite the much greater plaque load in AppNL-G-F mice.
At 20-months-old, there was a significant genotype ×
inter-stimulus interval interaction (p = 0·0004). AppNL-F
mice showed a similar decreased paired-pulse facilitation
to that observed at 9-months-old (Sidak multiple com-
parisons versus wild type, 25 ms: p = 0·00007; 50 ms: p =
0·2). In AppNL-G-F mice, the effect increased further, with
evoked EPSCs displaying paired-pulse depression rather
than facilitation (Sidak multiple comparisons versus wild
type, 25 ms p = 1 × 10−8; 50 ms p = 0·003).
Finally, to confirm that the lower paired-pulse ratio re-
flects a change in glutamate release probability, unitary
responses were evoked in a subset of 20-month-old ani-
mals. The proportion of stimuli that failed to elicit a re-
sponse was lower (one-way ANOVA, p = 0·008) in both
AppNL-F (Holm-Sidak post-hoc test, p = 0·013) and
AppNL-G-F (p = 0·007) mice compared to wild types (Fig.
3c), reflecting greater glutamate release probabilities.
Spontaneous inhibitory postsynaptic currents
To ascertain whether there were any network-level alter-
ations in inhibitory synaptic transmission, spontaneous
currents were recorded in the absence of neurotransmitter
receptor antagonists (i.e., prior to the addition of gabazine
to isolate EPSCs). (It should be noted that using CsCl as
an internal solution and a membrane holding potential of
–70mV gives rise to inward currents for both IPSCs and
Fig. 1 Plaques develop with age in AppNL-F and AppNL-G-F mice. a
and b) Examples of plaques detected using LCOs (green) in AppNL-F
(a) and AppNL-G-F (b) hippocampus at the ages indicated. DAPI
nuclear counterstain (blue). c) Median and upper quartile range for
Aβ pathology scores (0–5; Supplementary Fig.1). Sample sizes
(animals) are indicated within the bars. Sections (30 μm thick) were
labelled with LCOs and scored blind to experimental group. While
there was a significant effect of age (p < 0·0001) and there were no
significant differences between the sexes at any given age.
(Genotype effects were not assessed by age, as the progression of
plaques is known to be slower in AppNL-F than AppNL-G-F.) Note that,
for each animal, the score is the average of three sections, giving
one value per animal which may not be an integer
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EPSCs. Subtracting the frequency of pharmacologically
isolated EPSCs from this mixed population suggests that
> 90% of events are inhibitory; however, isolating EPSCs
using GABAA receptor antagonists disinhibits the slice, in-
creasing the frequency of EPSCs and thus IPSCs may re-
flect an even higher proportion in the mixed population.)
The frequency, amplitude and decay of spontaneous
IPSCs (Supplementary Fig. 3a-c) were found to be not
statistically different between the genotypes at any given
age, suggesting that there is little net change in inhibi-
tory synaptic transmission.
Long-term potentiation
Dendritic fEPSPs were recorded from CA3-CA1 synap-
ses (Fig. 4). The magnitude of LTP, determined as the
mean percent of baseline at 51–60min after a moderate
tetanic conditioning stimulus, was similar between geno-
types across all ages (Fig. 4c).
Although the magnitude of LTP was not affected in ei-
ther AppNL-F or AppNL-G-F mice, the older mice displayed
a possible change in the locus of expression (i.e. presynap-
tic versus postsynaptic alterations underlying the expres-
sion of LTP; see [31] for review). In wild types, although
paired-pulse facilitation tended to decrease after induction
of LTP compared to baseline (Fig. 4d), this was not statis-
tically significant (one sample t-test, 9-months-old p =
0·085; 20-months-old p = 0·16), suggesting a largely post-
synaptic locus of expression. In contrast, paired-pulse fa-
cilitation in AppNL-F decreased compared to baseline
following LTP induction (9-months-old p = 0·0080; 20-
months-old p = 0·049) and the significance of this change
following LTP induction was higher in AppNL-G-F (9-
months-old p = 0·014; 20-months-old p = 0·010). This
Fig. 2 Frequency of spontaneous excitatory synaptic transmission is reduced in an age-dependent manner in AppNL-F and AppNL-G-F mice. A)
Examples of continuous voltage-clamp recordings from CA1 pyramidal neurones in slices from 9- and 20-month-old wild type,
AppNL-F and AppNL-G-F animals illustrating the reduction in frequency of spontaneous EPSCs observed at these ages. Confirmed EPSCs are
indicated by the asterisks. B) Frequencies (i) and median amplitudes (ii) of spontaneous EPSCs in wild type and knock-in mice. C) Frequencies (i),
median amplitudes (ii) and decay time constants (iii) of miniature EPSCs in wild type and App knock-in mice. Data in panels B and C plotted as
mean ± SEM. Sample sizes (animals) are indicated by the numbers inside bars in subpanels i. Sequential Sidak corrected post-hoc comparisons to
wild type are indicated by * p < 0·05; *** p < 0·001 (9-months-old: AppNL-G-F p = 0·025; 20-months-old: AppNL-F p = 0·018, AppNL-G-F p = 0·00028)
Benitez et al. Molecular Neurodegeneration           (2021) 16:47 Page 6 of 20
change in paired-pulse ratio within genotypes suggests a
significant contribution of presynaptic mechanisms to
LTP expression; however, there was no significant differ-
ence across genotypes at either age.
Microglial immunohistochemistry
To determine the microglial response in App knock-in
mice, we performed immunohistochemistry for IBA1
(encoded by Aif1) and counted CA1 microglia (Fig. 5A).
The data were analysed using a GLMM permitting as-
sessment of age × genotype interactions within either
male or female mice.
Both age (p = 2·1 × 10−15) and genotype (p = 0·0010) had
main effects on microglial density, while there was no sig-
nificant effect of sex (p = 0·9). Moreover, there was a sig-
nificant age × genotype interaction within sex (p =
0·000021). Sequential Sidak comparisons indicated that
microglial density was greater in AppNL-F than age- and
sex-matched 24-months-old wild types (Fig. 5B); and that
microglial densities in AppNL-G-F were greater than age-
and sex-matched wild types from 9- to 24-months-old.
To assess the effect of plaque load on microglial density,
microglial density for each mouse was plotted against its
corresponding pathology score (Fig. 5C). Fitting sigmoidal
curves differentiated the AppNL-F and AppNL-G-F data (p =
0·0008). The sigmoidal fits (AppNL-F R2 = 0·52; AppNL-G-F
R2 = 0·76) indicated that AppNL-F develop microgliosis
with a lower plaque load than the AppNL-G-F.
Microglial gene expression
To complement the immunohistochemical analysis of
microgliosis, we used RT-qPCR to determine Aif1 levels
Fig. 3 Paired-pulse ratios of evoked excitatory postsynaptic currents are altered in an age-dependent manner in AppNL-F and AppNL-G-F mice. a)
Examples of evoked CA3-CA1 EPSCs in response to paired stimuli applied to Schaffer collaterals in slices from 20-month-old animals. b) Paired-
pulse ratios of CA3-CA1 EPSCs at ages indicated. Sample sizes (animals) are indicated by the numbers to the right of the 50ms data points.
Holm-Sidak post hoc tests compared to wild type are indicated by * p < 0·05; ** p < 0·01; **** p < 0·0001 (2-month-old: p = 0·0174; 7-month-old:
p = 0·019; 9-months-old AppNL-F 25 ms p = 3·4 × 10−8, AppNL-G-F 25 ms p = 1·1 × 10−7, AppNL-F 50 ms p = 0·0086, AppNL-G-F 50 ms p = 0·021; 20-
month-old AppNL-F 25 ms p = 7.5 × 10−5, AppNL-G-F 25 ms p = 6·0 × 10−9, AppNL-G-F 50 ms p = 0·0034). c) Failure rates of unitary evoked EPSCs in 20-
month-old wild type and App knock-in animals. Holm-Sidak post hoc tests compared to wild type are indicated by * p < 0·05; ** p < 0·01 (NL-F
p = 0·013, NL-G-F p = 0·0069). Data in panels B and C plotted as mean ± SEM. Sample sizes (animals) are indicated by the numbers within bars
Benitez et al. Molecular Neurodegeneration           (2021) 16:47 Page 7 of 20
in whole ipsilateral hippocampus of the same mice used
for immunohistochemistry. Similar to the immunohisto-
chemical data, Aif1 gene expression increased with age
(GLMM; p = 4·7 × 10−7). There was a main effect of
genotype (p = 0·053) and sex (p = 0·0037). The age ×
genotype interaction within sex reached p = 0·05 and
thus sequential Sidak comparisons were made. In both
sexes, Aif1 expression tended to be higher in AppNL-G-F
than wild types from 9-months-old. In females, this
reached significance at 18- and 24-months-old, while in
males significance was only obtained at 24-months-old
(Fig. 6Ai).
Fitting sigmoidal curves to the within animal compari-
son of Aif1 expression to Aβ pathology score differenti-
ated between AppNL-F and AppNL-G-F (Fig. 6Aii; p < 0.0001;
AppNL-F: R2 = 0.2; AppNL-G-F: R2 = 0.4). Thus, Aif1 expres-
sion increases at earlier plaque stages in AppNL-F than in
AppNL-G-F mice.
Increased expression of the microglial gene Trem2
For further characterisation of the microglial response,
the gene expression levels of the Alzheimer’s disease-
associated microglial gene Trem2 were examined (Fig.
6B). Initially, Trem2 levels were normalised to Actg1
Fig. 4 Altered locus of expression of long-term potentiation in AppNL-F and AppNL-G-F mice. a) Example CA3-CA1 fEPSPs recorded in stratum
radiatum of slices from 9-month-old animals. b) Example time courses of field EPSP slope, expressed as percent of mean baseline and relative to
induction tetanus. c) Summary of LTP magnitude across ages calculated as the mean of 51–60 min after conditioning. d) Paired-pulse ratio mean
of 51–60min after conditioning as a percentage of baseline. Data in panels C and D plotted as mean ± SEM. Sample sizes (animals) are indicated
in the bars within panel C. NB, at 9 and 20 months, while the paired-pulse ratio was significantly different from baseline for both App knock-in
lines and not for wild type, there was no significant difference between the groups (One sample t-tests versus 100%: * p < 0·05; ** p ≤ 0·01;
9-months-old AppNL-F p = 0·0080, AppNL-G-F p = 0·014; 20-months-old AppNL-F p = 0·049, AppNL-G-F p = 0·010)
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(encoding gamma-actin), the same house keeping gene
used for the Aif1 experiment above. These values reflect
global hippocampal Trem2 expression. The GLMM de-
scribed above was employed, revealing significant effects
of age (p < 1 × 10−20) and genotype (p = 4·0 × 10−9) but
not sex (p = 0·3). The age x genotype within sex inter-
action was also highly significant (p = 5·5 × 10−13). Se-
quential Sidak post hoc tests revealed that, for both
sexes, there was a significant increase in Trem2 expres-
sion from 9-months-old in AppNL-G-F but not AppNL-F
mice (Fig. 6Bi).
To confirm that the increase in Trem2 expression was
not a simple reflection of microglial proliferation (Fig. 5),
the expression of Trem2 was subsequently normalised to
Aif1 levels to give an estimate of Trem2 expression inde-
pendent of microglial numbers. The effects of age
(GLMM; p = 5.8 × 10−10) and genotype (p = 0.0023) were
maintained and an effect of sex became apparent (p =
0.012). The age × genotype within sex interaction term
also remained significant (p = 0.021). Sequential Sidak
comparisons indicated significant increases in Trem2 ex-
pression per microglial cell in AppNL-G-F mice from 9-
months-old but no changes in AppNL-F mice (Fig. 6Ci).
Comparisons of Trem2 expression to Aβ pathology
scores between AppNL-F and AppNL-G-F mice were made.
When normalised to Actg1 (Fig. 6Bii), sigmoidal fits to
the Trem2 expression relationship to Aβ pathology score
were unable to distinguish between the AppNL-F and
AppNL-G-F mice (p = 0·7) and thus a single curve was
used to fit both the AppNL-F and AppNL-G-F data sets
(R2 = 0·72). In contrast, when Trem2 expression was nor-
malised to Aif1 expression (Fig. 6Cii), the relationship to
Aβ pathology was fit by separate sigmoidal curves (p =
0·037; AppNL-F R2 = 0·1; AppNL-G-F R2 = 0·56). Thus,
Trem2 expression per microglia increases at earlier Aβ
plaque pathology stages in the AppNL-F mice than in the
AppNL-G-F but the maximal level of expression observed
in AppNL-F is less than that in the AppNL-G-F mice.
Fig. 5 Microgliosis occurs at an earlier plaque pathology stage in
AppNL-F than AppNL-G-F mice. A) Example of a ramified (left) and
amoeboid (right) microglial cell in CA1 of 9-month-old AppNL-G-F
mice. Scale bar for both images shown on right image. B) Densities
of IBA1+ microglia in male (panel i) and female (panel ii). A
generalised linear mixed model, with comparisons of Age ×
Genotype within Sex was followed by a sequential Sidak post hoc
analysis. ** p < 0.01; *** p < 0.001; **** p < 0.0001 with respect to
age- and sex-matched wild type (Males: 9-month-old p = 0·00048;
18-month-old p = 2·2 × 10−6; 24-month-old AppNL-F p = 0·016,
AppNL-G-F F p = 1·4 × 10−5; Females; 9-month-old p = 0·00031; 24-
month-old p = 0·0086). Data plotted as mean ± SEM. Sample sizes
(animals) are indicated within the bars. C) Sigmoidal fit to microglial
density plotted against corresponding pathology score for an
individual animal. Genotype is indicated by colour (red: AppNL-G-F;
blue: AppNL-F); both male and female data are included
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Microglial ablation – plaques and microglial activation
To understand the effect of microglia on plaque forma-
tion and subsequently explore interactions with synaptic
transmission we inhibited the microglial survival factor
CSF1R using PLX5622 [28]. Male mice were fed starting
from ages prior to plaque detection (1·5-months-old in
AppNL-G-F and 7-months-old in AppNL-F, along with age-
matched wild type controls) and continuing until pla-
ques were reliably detected. Following 2 (AppNL-G-F; Fig.
7A&B) or 3 (AppNL-F; Fig. 7F&G) months of treatment,
microglial density was partially (300 mg PLX5622/kg
food) or almost completely (1200 mg/kg) ablated,
Fig. 6 Microglial gene expression is upregulated at an earlier plaque pathology stage in AppNL-F than AppNL-G-F mice. Ai) Aif1 (the gene encoding
IBA1) gene expression determined by RT-qPCR expressed relative to the housekeeping gene Actg1 for males (left) and females (right). Sequential
Sidak post hoc analyses following GLMM are indicated by * p < 0·05; ** p < 0·01; *** p < 0·001; **** p < 0·0001; NS not significant (Males: 9-month-
old p = 0·36, 24-month-old p = 0·026; Females: 18-months-old p = 0·0013, 24-month-old p = 0·033). Aii) Sigmoidal fit to Aif1 expression plotted
against corresponding pathology score for an individual animal. Bi) Trem2 gene expression relative to the housekeeping gene Actg1, representing
a global Trem2 expression in the hippocampus for males (left) and females (right). Sequential Sidak post hoc analyses following GLMM are
indicated by *** p < 0·001; **** p < 0·0001 (Males: 9-months-old p = 0·00015, 18-months-old p = 4·0 × 10−7, 24-month-old p < 1 × 10−20; Females: 9-
months-old p = 1·5 × 10−5, 18-months-old p = 8·2 × 10−8, 24-months-old p = 6·7 × 10−14). Bii) Sigmoidal fit to Trem2 expression relative to Actg1
plotted against corresponding pathology score for an individual animal. Ci) Trem2 gene expression relative to Aif1 gene expression, representing
a per-microglia Trem2 expression for males (left) and females (right). Sequential Sidak post hoc analyses following GLMM are indicated by *p <
0.05; ** p < 0·01; **** p < 0·0001 (Males: 9-months-old p = 0·0020, 18-months-old p = 0·019, 24-months-old p = 1·1 × 10−5; Females: 9-months-old
p = 0·026, 18-months-old p = 0·042, 24-months-old p = 0·0025). Cii) Sigmoidal fit to Trem2 expression relative to Aif1 plotted against corresponding
pathology score for an individual animal. Sequential Sidak post hoc analyses following GLMM are indicated by * p < 0·05; ** p < 0·01; *** p < 0·001;
**** p < 0·0001; NS not significant (p = 0·36). Data in subpanels i within A-C plotted as mean ± SEM. Sample sizes (animals) are indicated within
the bars in panel A
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Fig. 7 (See legend on next page.)
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irrespective of genotype and age. Two-way ANOVAs
within each age group revealed main effects of drug (p <
0·0001) but no effects of genotype (p = 0·2) or an inter-
action (p = 0·3). Sidak corrected simple comparisons
within drug revealed significance between all doses
within each age group (Fig. 7F&G).
Irrespective of genotype, PLX5622 decreased densities
of microglia that were CD68+, a marker for a phagocytic
activation state (Fig. 7Ci&Hi). Two-way ANOVA re-
vealed a significant main effect of drug (p < 0·0001 at
both ages) but no effect of genotype (p > 0·5 at both
ages) nor an interaction (p > 0·5 at both ages). Sidak cor-
rected simple comparisons within drug indicated that all
doses were significantly different from each other (Fig.7-
Ci&Hi) except for 300 mg/kg versus 0 mg/kg within the
3·5-month-old group (p = 0·3).
Notably, although the number of CD68+ microglia de-
creased, the proportion of the remaining microglia that
were CD68+ increased with drug treatment (Fig. 7Cii&-
Hii; two-way ANOVA, p < 0.0001 for both age groups).
There were no significant main effects of genotype for
either age group (p = 0·11 and p = 0·078, respectively),
nor were there drug × genotype interactions (p = 0·2 and
p = 0.8, respectively). Sidak corrected simple compari-
sons within drug indicated that all doses were signifi-
cantly different from each other (Fig. 7Cii&Hii) except
for 1200mg/kg versus 300 mg/kg within the 10-month-
old group (p = 0·9).
Plaque development was assessed in these mice (Fig.
7A,D,F&I). While the percentage plaque coverage of the
hippocampus was not significantly different between the
doses (one-way ANOVA, AppNL-G-F: p = 0·3; AppNL-F:
p = 0·6) nor was the density of plaques within the hippo-
campal region per section (AppNL-G-F: p = 0·6; AppNL-F:
p = 0·5), there was a change in the density of small pla-
ques in AppNL-G-F mice (Fig. 7D). In AppNL-G-F, there
was a significant effect of plaque size (p < 0·0001; re-
peated measures two-way ANOVA), simply reflecting
more small than large plaques. While there was no main
effect of drug (p = 0·1), there was a significant size ×
drug interaction (p = 0·0040). Dunnett’s comparisons
within plaque-size bins showed significant effects of both
300 mg/kg (p = 0·0002) and 1200 mg/kg (p < 0·0001)
PLX5622 for plaques up to 200 μm2 but not for larger
plaques. In AppNL-F mice, there was a significant main
effect of size (p < 0.0001) but no effects of dose (p = 0·9)
or interaction (p = 0·9; Fig. 7I).
Microglia ablation – synaptic transmission
The effects of PLX5622 on paired-pulse ratios in 3·5-
month-old animals (Fig. 7E) were assessed using two-
way ANOVAs within inter-stimulus interval. There was
a significant main effect of drug (p = 0·018) at 25 ms but
no effect of genotype (p = 0·3) or dose × genotype inter-
action (p = 0·3). Simple Sidak-corrected comparisons of
drug dose indicated that 300 mg/kg (p = 0·026) but not
1200 mg/kg PLX5622 (p > 0·5) was significantly different
from control; 300 mg/kg versus 1200 mg/kg PLX5622
reached p = 0·075. There were no significant differences
at the 50 ms interval.
In 10-month-old mice, the low-dose PLX5622 mark-
edly reduced paired-pulse ratios, preventing paired-pulse
facilitation in wild type and exacerbating the reduced ra-
tios in AppNL-F mice (Fig. 7J). The high-dose PLX5622
had little effect in either genotype. A two-way ANOVA
within the 25 ms inter-stimulus interval revealed a sig-
nificant main effect of dose (p < 0.0002) but not geno-
type (p = 0·4) and a significant dose × genotype
interaction (p = 0·036). Simple Sidak-corrected compari-
sons within drug indicated that 300mg/kg (p < 0·0001)
but not 1200mg/kg PLX5622 (p > 0·2) was significantly
different from control; the significance of the difference
between 300 mg/kg and 1200mg/kg PLX5622 reached
p = 0·02. At the 50ms inter-stimulus interval, there was
a significant main effect of dose (p = 0·024) but no effect
of genotype (p = 0·2) or dose × genotype interaction (p =
(See figure on previous page.)
Fig. 7 Depletion of microglia using PLX5622 reduces the presence of small plaques but exacerbates the paired-pulse ratio effects of App knock-in
mice. Red and blue timelines indicate the PLX5622 feeding regimen for App knock-in mice and age-matched wild types. The first age indicates the
start of treatment, the second the age animals were killed for experimentation. A&F) Fluorescent micrographs of AppNL-G-F (A) and AppNL-F (F) CA1
region of the hippocampus following labelling of Aβ with LCOs and fluorescent immunohistological staining for IBA1 and CD68. Stratum oriens
(SO), stratum pyramidale (SP), stratum radiatum (SR) and stratum lacunosum moleculare (SLM) are indicated in the no-drug AppNL-G-F condition (for
further orientation, the stratum moleculare (SM), stratum granulosum (SG) and hilus (H) within the dentate gyrus are also shown). Scale bar in NL-
G-F 1200 mg/kg PLX image is 200 μm. B&G) Densities determined as cells that were IBA1+ microglia. Two-way ANOVA revealed significant main
effects of drug (AppNL-G-F p < 0·0001; AppNL-F p < 0·0001). C&H) Densities of IBA1+ microglia that were also CD68+ in the CA1 region of AppNL-G-F
(C) or AppNL-F mice. Data are presented as total density (i) and proportion of IBA1+ microglia (ii). Sample sizes (animals) for panels B and C are
indicated within the bars of panel B; and for panels G and H are indicated in panel G. In panels B,C,G&H, Sidak corrected simple comparisons
within drug are indicated by * versus control (0 mg PLX5622/kg food) and † versus 300 mg/kg; † p < 0·05; ** p < 0·01; *** p < 0·001; ****/†††† p <
0·0001. D&I) Plaque size histograms. Dunnett’s post hoc test for within plaque size bin comparisons to 0 mg/kg PLX5622 are indicated by *** p <
0·001 and **** p < 0·0001. Sample sizes (animals) are indicated within the parentheses in the legends. E&J) Paired-pulse ratios from PLX5622-
treated. In wild type (Ei and Ji) and AppNL-G-F (Eii) or AppNL-F (Jii) mice. Sample sizes are indicated in the legend. For simplicity in panels E&J, only
Sequential Sidak comparisons within drug dose versus control at the 25 ms inter-stimulus interval are indicated * p < 0·05; **** p < 0·0001; see
main text for further details. Data in panels B-E and G-J plotted as mean ± SEM
Benitez et al. Molecular Neurodegeneration           (2021) 16:47 Page 12 of 20
0·7). Simple comparisons of PLX5622 dose with Sidak
post hoc corrections indicated that the significance of
the difference between control and low-dose PLX5622
reached p = 0·020. (Neither control versus high-dose, or
low-dose versus high-dose were significant, p = 0·4.)
To test that changing our standard grain-based mouse
diet to the refined diet in which PLX5622 was provided
did not unexpectedly change paired-pulse ratios, we
compared data presented in Fig. 3 to the control diet.
The change of diet had no significant effect on paired-
pulse ratios in either genotype (Supplementary Fig. 4).
Thus, the lower paired-pulse ratio in 9-month-old
AppNL-F mice was confirmed in an independent 10-
month-old cohort fed the refined diet.
Thus, partial removal of microglia, more so than total
ablation, renders paired-pulse ratios in older wild types
similar to those of App knock-ins and, furthermore, ex-
acerbates the App knock-in phenotype without altering
the plaque load of the mice.
Discussion
App knock-in mice avoid many problems associated with
transgenic models, particularly overexpression and in-
appropriate expression driven by non-endogenous pro-
moters. Importantly, when these confounding factors are
removed, the key phenotypes observed in TASTPM
(APPSwe/PSEN1M146V) transgenic mice from our previ-
ous studies are maintained [9, 10]; see also [27]. How-
ever, the timing and magnitude of these phenotypes are
different, both across transgenic and knock-in models
and between the two knock-in models (summarised in
Fig. 8). Also of note is that we find little evidence for dif-
ferential effects between sexes in either microglial prolif-
eration or expression of microglial genes.
Increased probability of release is consistent across
mouse models
The simplest interpretation of the decreased paired-
pulse ratio is an increased probability of glutamate re-
lease [30]. Indeed, at TASTPM CA3-CA1 synapses, we
reported a reduction in failures to release neurotransmit-
ter [9] and here we confirm this in the oldest group of
App knock-in mice. Modulating probability of release
appears to be a physiological role of Aβ [32, 33], which
is released in an activity-dependent manner at or near
the synapse following endocytosis and processing of
APP [34]. In support of the role of synaptic modulation,
conditional knockout of App indeed reduced probability
of glutamate release as mouse CA3-CA1 synapses, likely
reflecting the role of Aβ, although other APP metabo-
lites could also mediate the effect [35]. Extensive reviews
of the controversial hypotheses surrounding the regula-
tion of neurotransmitter release in Alzheimer’s disease
are provided in references [36, 37].
Two mechanisms by which Aβ may increase the prob-
ability of glutamate release are pertinent: Increased synap-
sin 1 phosphorylation following enhanced Ca++ influx and
calcium/calmodulin kinase IV activity, which results in
greater synaptic vesicle availability [38, 39]; and disruption
of the interaction of synaptophysin 1 with VAMP2, thus in-
creasing the availability of VAMP2 to participate in the
SNARE complex and mediate neurotransmitter release
[40]. Interestingly, gene expression of other SNARE pro-
teins are altered in mouse models of Alzheimer’s disease,
including in our previous data published on www.mouseac.
org. For example, Snap25 is reduced in TASTPM mice. A
halving of SNAP25 using siRNA in immature primary hip-
pocampal neurones, rather than impairing neurotransmitter
release, unexpectedly results in a shift from paired-pulse fa-
cilitation to paired-pulse depression [41]. Thus, while
SNAP25 is critical for neurotransmitter release, partial re-
duction can result in an increase in probability of release.
Other presynaptic markers, including Syt1 and Syp (encod-
ing synaptotagmin-1 and synaptophysin, respectively), show
reductions in expression in TASTPM transgenic mice
(www.mouseac.org) and also in patients [42, 43]. While a
reduction in any one of these proteins may be predicted to
impair vesicle release, the complex phenotype associated
with variable reductions in these and the SNARE proteins
is harder to predict. Indeed, multiple knock-out of similar
genes results in an increased release probability [44], similar
to that observed here.
Thus, increased release probability is common to
transgenic and knock-in models and starts before plaque
deposition (Fig. 8), presumably in response to rising sol-
uble Aβ levels. The loss of this effect in AppNL-G-F mice
with a moderate plaque load and the later observation
that AppNL-F and AppNL-G-F mice show similar magni-
tude effects despite a heavier plaque load in AppNL-G-F
mice, likely reflect the strong equilibrium shift towards
Aβ deposition caused by the Arctic mutation [25]. In-
deed AppNL-G-F mice have lower soluble Aβ levels than
AppNL-F mice, despite heavier plaque loads [21]. As sol-
uble Aβ is the more likely mediator of synaptic modula-
tion, it is less surprising that removing soluble Aβ from
the neuropil (caused by the Arctic mutation sequestering
it into plaques) results in an alleviation of the phenotype.
Presumably, there is always some soluble Aβ in the im-
mediate vicinity of the plaque, even in AppNL-G-F mice,
resulting in a return of the phenotype when the plaque
load across the whole neuropil is heavy enough for most
synapses to be within this close range.
Temporal differences in loss of spontaneous action
potentials between models
The loss of spontaneous action potentials (i.e. spontan-
eous EPSCs), identified before plaque deposition in
transgenic mice, is much later in App knock-in mice. In
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AppNL-G-F mice, this only occurs from 9-months-old,
when the plaque load is very heavy and coinciding with
the re-emergence of altered paired-pulse ratios. In
AppNL-F mice, this loss is even later, at 20-months-old
and much later than changes in release probability.
While the plaque load is quite heavy at this stage, it is
substantially less than in the 9-months-old AppNL-G-F
mice. This is also consistent with an effect of soluble Aβ
affecting synapses more distal from plaques in the
AppNL-F than occurs in AppNL-G-F mice. The loss of
spontaneous synaptic activity prior to plaque deposition
in transgenic mice likely reflects the much higher levels
of soluble Aβ in these APP overexpressing mice. Avoid-
ing overexpression has resulted in a temporal separation
of the increased release probability (occurring prior to
plaque deposition) and loss of spontaneous action po-
tentials (only occurring once a substantial plaque load is
evident) in the knock-in mice, which were concomitant
in the transgenic animals and preceded plaque depos-
ition. Thus, it may be that the loss of spontaneous action
Fig. 8 Summary timelines of phenotypes in APP knock-in and transgenic mice. Timelines for indicated phenotypes in AppNL-F (left), AppNL-G-F
(centre) and TASTPM transgenic mice (right). AppNL-F and AppNL-G-F data are all included in the current publication. TASTPM data were published
in Matarin et al., 2014; Cummings et al., 2015; and Medawar et al., 2019 (a preliminary comparison was presented in Joel et al., 2018). Note the
phenotypic development in relation to plaque deposition within each mouse model and across the three models. Magnitudes of change across
different phenotypes are not necessarily proportional; however, within any given phenotype, magnitudes of change across genotypes are
proportional. Microgliosis refers to densities of IBA1+ microglia. Probability of glutamate release is based on paired-pulse ratio data. Spontaneous
and miniature EPSCs reflect changes in frequency
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potentials is a homeostatic response to the increased
glutamate release; it certainly is not the reverse (see [45]
for review). Importantly, this consistency of phenotypes
between models suggests that increased release probabil-
ity is likely the earliest effect of rising Aβ levels.
We do not see the increase in probability of release, indi-
cated by the decreased paired-pulse ratio and reduced fail-
ure rate, reflected as an increase in frequency of miniature
(or spontaneous) EPSCs. This may reflect that the increase
in probability of release is counteredbalanced by a reduc-
tion in the number of synapses, supported by a reduction
in synaptophysin and PSD95 immunoreactivity in AppNL-F
mice from 9months of age [21]. Alternatively, it would be
pertinent to investigate differences in vesicle pools that
underlie the various forms of synaptic transmission. The
immediately releasable pool underlies synchronous release
of neurotransmitter, i.e. glutamate release in response to an
action potential, and typically consists of a single vesicle at
hippocampal synapses and thus results in quantal (i.e. single
vesicle) release [46]. In contrast, asynchronous release, i.e.
glutamate release underlying the stochastic miniature cur-
rents, arises from a pool of vesicles that are very close to
but not fully primed for release, referred to as the readily
releasable pool [46]. Thus, our data indicate that regulation
of the immediately releasable pool may be altered, while
the readily releasable pool may be unaffected.
The increase in release probability due to soluble Aβ,
even before plaque deposition is consistent with observa-
tions in vivo in transgenic mice of increased activity in
many neurones in the network (reviewed in [47]). More-
over, this effect is shown to persist in these in vivo stud-
ies especially in the vicinity of plaques where soluble Aβ
would be expected to be highest. Although we do not
see an increase in spontaneous (including miniature)
glutamatergic activity in the present study, nor in our
previous study in transgenic mice, this is likely a differ-
ence between in vivo recordings at physiological temper-
atures with the full neuronal network intact versus
in vitro acute brain slice recordings at room
temperature, in which much of the recurrent activity is
likely to be truncated. Moreover, the present recordings
were in the presence of a GABAergic antagonist, which
greatly decreased the effects reported in vivo. It should,
however, be noted that we do not see alterations in
spontaneous GABAergic IPSCs, either here in App
knock-in mice, or previously in transgenic mice [10],
which is consistent with the observation that
palvalbumin-positive interneurones, despite showing
some neuritic dystrophy, are otherwise normal in
AppNL-F mice [48]. Thus, we would not suggest that we
could assess the overall physiological network effects of
Aβ in the present study but can be confident about the
changes seen in individual synapses. It would be inter-
esting to undertake equivalent in vivo studies in the
knock-in mice to address the question of whether these
network changes are dependent on overexpression or
other artefacts of transgenic technology.
Synaptic plasticity is intact
Data from transgenic mice suggest that Aβ has a role in
the induction and consolidation of LTP, with several labs
reporting either its absence or even induction of long-
term depression rather than LTP (reviewed in [37]). We
have reported a biphasic effect on magnitude of LTP in
transgenic mice [10], with an increase in LTP when Aβ
levels initially increase but a subsequent reduction in
LTP following plaque deposition. Recently it was re-
ported that both early (1–2 h) and late (4 h) LTP is im-
paired in AppNL-G-F mice at 6–8 months [49]. However,
we do not replicate this phenotype in the knock-in
models, even at advanced ages. This discrepancy could
be an effect of employing different LTP induction para-
digms or Latif-Hernandez and colleagues’ choice of the
AppNL knock-in mouse as control, which presents with
raised soluble and insoluble Aβ above wild type levels
[21] and > 10-fold higher soluble Aβ40 than AppNL-G-F
[49]. Given soluble Aβ40 monomer and dimers increase
release probability [33], this complicates the interpret-
ation. While we find no deficits in LTP induction com-
pared to wild type mice, a more complex phenotype is
observed, whereby there is a loss of postsynaptic mecha-
nisms of expression counterbalanced by enhanced pre-
synaptic mechanisms as AppNL-F and AppNL-G-F mice
age. As wild type mice age, a similar but non-significant
trend is seen, suggesting the increase in plaque load ex-
acerbates the effect of normal ageing. Notably, all the
functional synaptic changes seen in App knock-in mice
are presynaptic, suggesting that much of the postsynap-
tic change reported in transgenic mice may be artefacts
of transgenic mice.
Microglia and plaques
Microglial phenotypes have been long-established as part
of Alzheimer’s disease pathology. Indeed, Alois Alzhei-
mer noted a glial phenotype alongside plaques and
neurofibrillary tangles [50]. More recently, genome-wide
association studies highlight that microglial genes are
the main groups of risk-genes for Alzheimer’s disease
[for example see [51].
In the Alzheimer’s diseased brain, microglia cluster
around plaques, which has led to the notion that
microglia clear plaques. However, it appears that they
are largely ineffective at directly phagocytosing Αβ,
both in vitro or in vivo [for example, see [52]. Here
we confirm previous reports suggesting that removal
of microglia does not increase plaque load [53, 54];
but see the recent article [55]. Indeed, if anything, in
our hands there are fewer of the smallest, presumably
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most recently deposited plaques, when the microglia
are removed with a CSF1R inhibitor. This is consist-
ent with microglia moderating the initial development
of plaques [28] but, as we report the same density
and coverage of plaques at early stages, microglia
probably do not mediate seeding of plaques. We re-
cently proposed that it is more likely that synaptic
toxicity imparted by Aβ induces microglia to phago-
cytose damaged synapses rather than Aβ, limiting the
spread of damage [18]. Supporting the suggestion that
microglia phagocytose synapses, a recent prepublica-
tion shows adult human microglia containing synaptic
proteins and that synapses derived from Alzheimer’s
disease brain are phagocytosed more readily [56]. Al-
ternative roles for microglia in Aβ handling have been
proposed, including compacting Aβ via TREM2-
dependent mechanisms [57, 58] or clearing Αβ via
non-phagocytic mechanisms [summarised in 52].
Interestingly, when microglial numbers were depleted,
irrespective of the presence of plaques, the remaining
microglia were predominantly CD68+. It is not clear
whether CD68+ microglia are more resistant to CSF1R
inhibitors or that the remaining microglia shift towards
a phagocytic phenotype. Certainly, in the AppNL-G-F
mice, the density of CD68+ microglia was unchanged by
the low-dose of PLX5622 compared to untreated mice,
despite a halving of the total microglia.
Ablation of microglia exacerbated the decrease in
paired-pulse ratio in App knock-in mice. This surprising
phenotype was more pronounced in response to partial
removal of microglia than near-complete ablation, sug-
gesting that the remaining CSF1R-inhibited and mostly
CD68+ microglia have an active effect, rather than the
loss of microglia being the cause of the change. Given
that removal of microglia exacerbated synaptic pheno-
types in both lines of App knock-in mice, microglia are
likely protective in mouse models and human disease. It
should be noted that 10-month-old wild type mice also
responded with a reduced paired-pulse ratio. So, while
loss of microglial function may be damaging in Alzhei-
mer’s disease, this is not a disease-specific phenomenon
but a change in the same direction, exacerbated in dis-
ease. Intriguingly, Trem2 haploinsufficient mice have a
greater microglial response to neuronal injury than wild
type mice or those with complete knock-out of the gene.
Moreover, Trem2 haploinsufficiency increases tau path-
ology, proinflammatory markers and atrophy in trans-
genic mutant human tau mice. Conversely, complete
Trem2 deficiency is protective in the tau mice [59].
If reactive microglia do indeed mediate some of the
phenotypes mediated here, there are several routes by
which they may exert effects. One is a direct interaction
of microglia and neurones, which the shift towards a
CD68+ profile suggests as being increased phagocytosis.
As already discussed, we suggest that this is phagocytosis
of damaged synapses surrounding plaques, rather than
of plaques per se [18] and that this limits the spread of
damage but may later become detrimental as the num-
ber of synapses (or, indeed, neurites) excised damage
overall network activity. In parallel to this, it has been
proposed that the profiles of microglia change during
disease progress, in particular there is shift in the gene
profiles towards more proinflammatory markers [60].
This shift is reflected in the App knock-in mice [61]
(which is also true for transgenic mice, e.g. [13, 15, 62]).
In addition, the neuronally-released cytokine IL33, has
been shown to regulate microglia such that they pro-
mote structural synaptic plasticity by remodelling the
extracellular matrix and promotes fear conditioned
learning [63]. Extending that role into a transgenic
mouse model of Alzheimer’s disease, IL33 shifted the ac-
tivation state of microglia from a proinflammatory pro-
file towards a profile expressing anti-inflammatory genes
with improved phagocytosis and again improved fear-
conditioned learning [64]. Thus, it appears that micro-
glia can directly modulate synaptic structure, function
and, ultimately, behaviour of the animal, particularly
during disease states.
Contrasting phenotypes in the App knock-in mice is likely
due to the Arctic mutation
The lack of electrophysiological and microglial pheno-
types in the AppNL-G-F mice when plaques first appear is
in contrast to the clear effects in both transgenic mice
[9, 10] and AppNL-F mice at an equivalent stage of Aβ
pathology. This cannot be an effect specific to 4-month-
old animals because the transgenic mice maintain micro-
gliosis and altered release probability at this age (Fig. 8).
Again, lower soluble Aβ levels due to the higher propen-
sity for Aβ fibrillation imparted by the Arctic mutation
may be the cause. So, while the AppNL-G-F model is at-
tractive as it presents with rapid plaque formation, its
usefulness as a model for Alzheimer’s disease is in un-
derstanding how folding of Aβ and proximity to plaques
affect phenotypes. In contrast, the mutations in AppNL-F
mice are restricted to the β- and γ-secretase cleavage
sites flanking the Aβ sequence and are thus used as a
tool to trigger the raise in Aβ levels observed in sporadic
Alzheimer’s disease. Importantly, despite the more rapid
plaque deposition in AppNL-G-F, phenotypes are more
pronounced and at earlier Aβ pathology stages in the
AppNL-F mice.
Another consideration in comparing models is the
choice of control. Until now the wild type mouse has
been the best available control but this has its limita-
tions. The difference in sequence between human and
mouse APP alters the affinity for β-secretase. Humanis-
ing App increases levels of Aβ compared to wild type
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mice [65], suggesting that even with knock-in mice,
some of the changes may be exaggerated when com-
pared to wild types. The humanised App mouse will be
an improved control in future studies.
Given that Aβ is a physiological protein, its basal ef-
fects are likely beneficial. Indeed, the proposed overall
physiological function of Aβ is to improve memory [66].
We propose that increased neurotransmitter release me-
diated by Aβ is a protective response to events such as
head trauma, ischaemia or other synaptic insults. If these
insults are short-lived, Aβ levels return to normal, re-
storing neuronal activity. However, in individuals with
either impaired Aβ clearance, deficient immune function
or in which the cause of the Aβ elevation persists, for
example in chronic conditions such as high-blood pres-
sure and type II diabetes (both risk factors for Alzhei-
mer’s disease), Aβ levels will remain raised. Extended
periods of high Aβ levels will maintain altered synaptic
function and potential to homeostatic responses and
lead to plaque deposition, tau hyperphosphorylation and
dystrophic neurites. In mice, this is the extent of path-
ology; however, humans progress to neurofibrillary tan-
gles and neurodegeneration. The AppNL-F mice provide
a background of rising Aβ which likely mimics early
stages of disease without the artefacts of transgenic mice
and provides a good base model for the addition of fur-
ther risk-factors that may lead to improvements in the
available models and understanding of the disease.
Conclusions
Increased probability of glutamate release precedes
plaque deposition, is consistent across transgenic and
knock-in mouse models of Alzheimer’s disease and likely
reflects the acute physiological effect of Aβ. Inappropri-
ately prolonged increases in glutamate release maintains
aberrant synaptic transmission and thus may result in
homeostatic changes, such as the decrease in action po-
tential firing observed here. Given the positive regulation
of glutamate release by activity-dependent release of Aβ
[32], a positive feed-back may be triggered by dysregu-
lated Aβ release or clearance. Ever increasing levels of
amyloid beta would lead to deposition and subsequent
damage around plaques [67]. However, the effects of pla-
ques may well depend on their structure, as indicated by
the differential time course of AppNL-G-F compared to
AppNL-F at similar plaque loads, which likely reflects, in
this instance, the Acrtic mutation pushing the Aβ equi-
librium from soluble towards insoluble forms, creating
more dense plaques. However, differences in structure
may also exist within sporadic forms of the disease and
thus variations in the halo of oligomeric forms of Aβ
surrounding plaques [68] may influence their effects on
synaptic function or toxicity.
Microglia also respond to increased Aβ levels by pro-
liferating and upregulating CD68 and Trem2. Partial de-
pletion of microglia indicated that the surviving
phagocytic microglia, rather than their absence, likely
drive the age-dependent effect on glutamate release that
becomes exacerbated in Alzheimer’s disease.
We also shed light on which of the previous reports
from transgenic mice can be validated in knock-in mice.
This is the first detailed characterisation and comparison
of the relationship between plaques, synaptic transmis-
sion and microglial activity throughout life in the two
App knock-in mouse lines AppNL-F and AppNL-G-F, in
which overexpression and other artefacts associated with
transgenic technology are avoided.
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